Medrx Co

Medrx Co R&D Expenses

The Research & Development Expenses of Medrx Co (4586.T) as of Nov 19, 2026 is 838.82 M JPY. In the previous year, Research & Development Expenses was 809.81 M JPY — a change of 3.58% (higher).

R&D Expenses

838.82 MJPY

YoY

3.58%

Last updated:

Research & Development Expenses of Medrx Co is 2025 838.82 M JPY. Research & Development Expenses of Medrx Co was 2024 809.81 M JPY. It decreases by 3.58% higher compared to the previous year.

The Medrx Co R&D Expenses history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D Expenses
Date
R&D Expenses
Jan 1, 2018
943.63 M JPY
Jan 1, 2019
1.47 B JPY
Jan 1, 2020
914.70 M JPY
Jan 1, 2021
737.13 M JPY
Jan 1, 2022
877.75 M JPY
Jan 1, 2023
694.12 M JPY
Jan 1, 2024
809.81 M JPY
Jan 1, 2025
838.82 M JPY
The Medrx Co R&D Expenses history
YEARR&D ExpensesYoY
838.82 MJPY+3.58%
809.81 MJPY+16.67%
694.12 MJPY-20.92%
877.75 MJPY+19.08%
737.13 MJPY-19.41%
914.70 MJPY-37.98%
1.47 BJPY+56.31%
943.63 MJPY+13.41%
832.02 MJPY-18.43%
1.02 BJPY+58.41%
643.91 MJPY-3.88%
669.89 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Medrx Co Stock analysis

What does Medrx Co do? Medrx Co. Ltd. develops pharmaceutical drugs using transdermal absorption technology, focusing on percutaneous absorption through ionic liquid transdermal system (ILTS) and nano-sized colloid transdermal system (NCTS). The company aims to maximize drug efficacy, reduce side effects, and provide alternatives for patients who cannot take oral medications. Its products target new markets by offering medicines with enhanced delivery systems and added value. The firm's technology includes ionic liquid transdermal system (ILTS) leveraging ionic liquid characteristics and nano-sized colloid transdermal system (NCTS) utilizing nano colloidization technology. These systems enable precise drug delivery, addressing challenges in oral administration and improving patient compliance. The company's products are designed to serve patients requiring non-oral medication options. Medrx Co. Ltd. produces medicines based on percutaneous absorption formulation technology, targeting healthcare providers and patients who need alternative drug administration methods. The company's focus on transdermal systems allows it to address specific medical needs, such as preventing forgotten doses and reducing side effects associated with traditional oral drugs. Medrx Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Medrx Co stock

Research & Development Expenses of Medrx Co is 838.82 M JPY in 2025.

Research & Development Expenses of Medrx Co changed from 809.81 M JPY to 838.82 M JPY, representing a 3.58% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Research & Development Expenses Medrx Co since 2006 – with annual values, charts, and detailed analysis.

R&D expenses represent the costs incurred in researching and developing new products, services, or processes. High R&D spending can signal innovation and future growth potential.

Research & Development Expenses's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Research & Development Expenses's Medrx Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Medrx Co

All Key Metrics — Medrx Co